Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis.

A statistically significantly higher proportion of patients receiving lanadelumab had no chronic pain compared with those receiving other long-term prophylaxis.

• 58.1% of lanadelumab patients had no chronic pain versus 38.1% of other LTP patients.
• The difference was statistically significant (p = 0.0023).
• Data were drawn from a cross-sectional survey conducted from January 2023 to January 2024 in the United States.
• Physicians reported data on 86 patients treated with lanadelumab and 84 treated with other LTP.

A statistically significantly higher proportion of patients receiving lanadelumab had no chronic fatigue compared with those receiving other long-term prophylaxis.

• 51.2% of lanadelumab patients had no chronic fatigue versus 34.9% of other LTP patients.
• The difference was statistically significant (p = 0.0037).
• Chronic fatigue outcomes were physician-reported at the time of the survey.

More patients receiving lanadelumab had 'very good' physician-reported quality of life and less patient-reported QoL impairment compared with those receiving other long-term prophylaxis.

• The difference in physician-reported QoL and patient-reported QoL impairment was statistically significant (p = 0.0102).
• Both physician-reported and patient-reported QoL outcomes favored lanadelumab over other LTP.
• Outcomes were assessed at the time of the survey.

A higher proportion of patients receiving lanadelumab reported complete satisfaction overall with their treatment compared with those receiving other long-term prophylaxis.

• 30.2% of lanadelumab patients reported complete overall treatment satisfaction versus 17.9% of other LTP patients.
• The difference was statistically significant (p = 0.0144).
• Patient-reported satisfaction was assessed via a cross-sectional survey design.

A substantially higher proportion of patients receiving lanadelumab reported complete satisfaction with the efficacy of their treatment compared with those receiving other long-term prophylaxis.

• 44.2% of lanadelumab patients reported complete satisfaction with treatment efficacy versus 11.9% of other LTP patients.
• The difference was statistically significant (p < 0.0001).
• This was the largest proportional difference observed across all patient-reported satisfaction outcomes.

The study used a real-world, cross-sectional survey design with physician-reported and patient-reported outcomes for patients with HAE in the United States.

• Data were collected from January 2023 to January 2024.
• Physicians reported data on 86 patients treated with lanadelumab and 84 treated with other LTP.
• Outcomes assessed included attack and disease severity, pain, fatigue, QoL, and patient-reported outcomes.
• The authors noted limited real-world data comparing lanadelumab with other treatments as a gap motivating the study.